Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Depreciation & Amortization (CF) (2022 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Depreciation & Amortization (CF) for 4 consecutive years, with $23688.0 as the latest value for Q3 2025.

  • Quarterly Depreciation & Amortization (CF) rose 260.66% to $23688.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $60499.0 through Dec 2025, up 130.28% year-over-year, with the annual reading at $60499.0 for FY2025, 130.28% up from the prior year.
  • Depreciation & Amortization (CF) for Q3 2025 was $23688.0 at Inhibikase Therapeutics, down from $24157.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $159204.0 in Q2 2023, with the low at $1681.0 in Q3 2022.
  • Average Depreciation & Amortization (CF) over 4 years is $20836.7, with a median of $6568.0 recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) soared 290.72% in 2023, then plummeted 95.87% in 2024.
  • Over 4 years, Depreciation & Amortization (CF) stood at $5042.0 in 2022, then surged by 30.27% to $6568.0 in 2023, then decreased by 0.02% to $6567.0 in 2024, then soared by 260.71% to $23688.0 in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $23688.0, $24157.0, and $12654.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.